LTR Pharma Brings Roxus® Intranasal Vardenafil to U.S. Prescribers: Peak Plasma Levels in a Median of 10 Minutes Life Science Investing
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease Biotech Investing
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease Biotech Investing
RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial Life Science Investing
PharmaTher Launches M3DICINES National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies Life Science Investing
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Life Science Investing
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia Life Science Investing
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 Life Science Investing
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia Life Science Investing
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
